Syntagon introduces strategic pricing initiative

Leading contract research organisation, Syntagon, has unveiled a strategic pricing initiative that will see substantial cost savings for biotechnology and pharmaceutical customers taking compounds into phase I and phase II clinical trials.

“Now, more than ever, customers are under growing pressure to make their limited resources stretch further. Cost-efficiency is increasingly critical; and maintaining cash is of utmost importance, especially for smaller companies,” says John Cameron, Director of Sales and Marketing at Syntagon. The initiative has been made possible by Syntagon’s decade-long experience of driving operational efficiencies, by its burgeoning operations in Latvia and by its Shanghai sourcing office, that opened last year. Over the past 10 years, Syntagon has gained extensive experience in manufacturing and analysing clinical APIs for phase I and phase II clinical trials. Our comprehensive knowledge of the market has provided us with a solid foundation for increasing workflow, realising operational efficiencies and crucially, reducing costs for customers, while maintaining the highest quality and service standards at Syntagon’s facilities in Sweden, Latvia and China. “Our now fully-integrated unit in Riga, Latvia, provides a substantial cost advantage that in some cases allows us to pass on savings to our customers of up to 40 per cent on a typical GMP project, while still safeguarding quality of the highest calibre,” Syntagon CEO, Michael Lofthagen explains. “Furthermore, through our raw material sourcing office in Shanghai, we have already been able to introduce significant cost-savings on a number of projects,” Lofthagen adds. The pricing initiative is due to be introduced on a range of services throughout the year.

Tags: